论文部分内容阅读
多药耐药性（ＭＤＲ）是用化疗药物成功地治疗肿瘤的主要障碍之一。其机理涉及诸多因素。应用ＪＳＢ－１单克隆抗体，采用免疫组化（ＡＰＡＡＰ）对４２例急性白血患者ｍｄｒｌ基因天达产物Ｐ１７０进行检测，结果显示：Ｐ１７０表达率为３３．３％，其中初诊患者Ｐ１７０阳性率为２３．３％，复发患者５８．３％，初诊组阳性率明显低于复发组阳性率（Ｐ＜０．０５）。另外Ｐ１７０表达阴性组病人缓解率６７．９％显著高于阳性组缓解率２８．９％（Ｐ＜０．０５）。
Multidrug resistance (MDR) is one of the major obstacles to successful treatment of tumors with chemotherapeutic drugs. Its mechanism involves many factors. Using JSB-1 monoclonal antibody, 42 cases of acute white blood patients were detected by immunohistochemistry (APAAP). The P170 expression rate was 33.3%. The positive rate of P170 in newly diagnosed patients was 23%. 3% of the relapsed patients were 58.3%. The positive rate in the newly diagnosed group was significantly lower than that in the recurrent group (P<0.05). In addition, the response rate of 67.9% in patients with negative P170 expression was significantly higher than the response rate of 28.9% in positive patients (P<0.05).